《大行報告》里昂上調歐舒丹(00973.HK)目標價至38.8元 評級「買入」
里昂發表研究報告指出,歐舒丹(00973.HK)上半財年銷售額按年增長13%,按固定匯率計算增長19%;經營利潤率達11.3%,則低於預期,主要是由於Elemis營銷費用高於預期,以及2021財年錄得一次性疫情補貼。
報告引述管理層預計,新冠變異病毒株Omicron對零售市場影響有限,提高全財年經營指引,預期銷售額按年錄低至中雙位數增長,營業利潤率達到16%以上。該行預期,歐舒丹第三季勢頭強勁,加上Sol de Janeiro (SDJ)整合及下半財年一次性補貼影響將減少,重申其「買入」評級,目標價由36.6元上調至38.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.